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Abstract
Background: Stereotactic body radiation therapy (SBRT) applied by helical tomotherapy (HT) is feasible for lung
cancer in clinical. Using SBRT concurrently with erlotinib for non-small cell lung cancer (NSCLC) is not reported
previously.
Case Presentation: A 77-year-old man with stage III NSCLC, received erlotinib 150 mg/day, combined with image-
guided SBRT via HT. A total tumor dose of 54 Gy/9 fractions was delivered to the tumor bed. The tumor
responded dramatically and the combined regimen was well tolerated. After concurrent erlotinib-SBRT, erlotinib
was continued as maintenance therapy. The patient developed dyspnea three months after the combined therapy
and radiation pneumonitis with interstitial lung disease was suspected.
Conclusions: Combination SBRT, HT, and erlotinib therapy provided effective anti-tumor results. Nonetheless, the
potential risks of enhanced adverse effects between radiation and erlotinib should be monitored closely, especially
when SBRT is part of the regimen.
Background
Erlotinib, one of the epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs), is active and
relatively well tolerated in chemotherapy-naïve elderly
patients with advanced non-small cell lung cancer
(NSCLC) [1]. Image-guided stereotactic body radiother-
apy (SBRT) and helical tomotherapy (HT) using hypo-
fractionation in patients with early-stage medically
inoperable NSCLC is feasible and well tolerated [2]. For
stage III NSCLC, hypofractionation yields equivalent
survival rates, but without often fatal symptomatic pneu-
monitis, compared to conventional radiotherapy [3].
The addition of standard-dose erlotinib to chemora-
diotherapy is feasible, without an increase in toxicity [4].
Little information is available on fatal pulmonary toxi-
city due to irradiation pneumonitis when erlotinib is
concurrently given with SBRT and used thereafter as
maintenance therapy for NSCLC.
Case presentation
A 77-year-old man was diagnosed with NSCLC,
cT2N2M0, stage III A. Chest computed tomography (CT)
showed a soft tissue mass measuring 4 × 3.9 cm in the
right upper lung, with mediastinal lymphadenopathy. Car-
cinoembryonic antigen (CEA) was also elevated to 12.9
mg/dl. The Patient received oral erlotinib 150 mg/day as
the first line therapy. Three months later, the CEA
increased from 12.9 ng/ml to 29.1 ng/ml. Then, erlotinib
was added concurrently to the radiotherapy regimen. This
regimen comprised 54 Gy given in nine fractions delivered
with SBRT using HT, at 95% of the prescribed isodose for
the planned target volume. The split courses with 3 frac-
tions per week were prescribed. (Figure 1 and 2) Targeting
was based on new, separate CT scans for each split course.
The tumor volume (ml) vs. the right lung volume was
116.1 ml vs. 1282.9 ml in the first treatment course and
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The mean lung dose, V15, and V20, where Vx was the
percentage of lung volume that received at least × Gy
[5] for separate lung images, is shown Table 1. The
whole-course V20 and mean lung dose for the total
lung were 10% and 10.24 Gy, respectively. By 2.5
months after the combination therapy, the tumor shrank
f r o m4×3 . 9×4 . 5c mt o2 . 4×2 . 9×2 . 1c ma n de r l o t i -
nib 150 mg/day was prescribed as maintenance therapy.
Unfortunately, the patient developed dyspnea three
months after the combination therapy. He was trans-
f e r r e dt ot h em e d i c a li n t e n s i v ec a r eu n i t .I nas e r i e so f
image studies, opacities of a diffuse ground-glass pat-
tern, subpleural bleb formation in the marginal areas,
airspace consolidation and fibrosis in bilateral whole
lung fields were noted, and radiation pneumonitis was
suspected (Figure 3, 4, 5, 6) [6,7]. The patient received
empirical antibiotics, steroid therapy, antioxidant, and
supportive treatment. Four more months after the com-
bined therapy, the patient died of respiratory failure.
Conclusions
Image-guided SBRT with HT using hypofractionation in
patients with early-stage medically inoperable NSCLC is
feasible [2]. The hypofractionated scheme yields equiva-
lent survival rates, without fatal, symptomatic pneumo-
nitis for patients with stage III NSCLC when compared
with conventional radiotherapy [3]. Belderbos et al. [8]
reported that radiation dose escalation was safe up to
94.5 Gy in 42 fractions with a mean lung dose 13.6 Gy
or less in 6 weeks in NSCLC patients. The patients
underwent irradiation 5 days per week, and twice daily
when more than 30 fractions were prescribed, with at
least a 6-h interval in between each fraction. According
to linear-quadratic (LQ) modeling [9], the biologic effect
of 94.5 Gy/42 fractions converted to a hypofractional
dose of 6 Gy per fraction (EQD6), for which the acute
effects and late normal tissue effects would be equiva-
lent to 72 and 54 Gy, respectively. The mean lung dose
Figure 1 Dose distribution in the first treatment course.
Tomotherapy treatment planning with high conformity (conformal
index, CI = 1.03). Red, green, and blue areas are 100%, 90%, and
50% of the prescribed radiation dose, respectively. The blue dots
outline the lung structure and the sky-blue dots indicate the
radiation target.
Figure 2 Dose distribution in the second treatment course.
Tomotherapy treatment planning with high conformity (conformal
index, CI = 1.03). Red, green, and blue areas are 100%, 90%, and
50% of the prescribed radiation dose, respectively. The blue dots
outline the lung structure and the sky-blue dots indicate the
radiation target.
Table 1 Mean lung volume, dose, V15, and V20 for each
lung in the first and second radiotherapy courses, with 2
weeks interval between radiotherapy courses
First course (0-36 Gy) Second course (36-54 Gy)
Right lung
volume,
1167 ml
Left lung
volume,
1244 ml
Right lung
volume,
1385 ml
Left lung
volume,
1490 ml
Mean
lung
dose (Gy)
10.77 Gy 4.74 Gy 4.63 Gy 1.96 Gy
V15* (%) 27% 2% 13% 0%
V20* (%) 22% 0% 8% 0%
*V15 and V20 are the percentages of lung volume that receive at least 15 and
20 Gy in the ipsilateral and contralateral lungs.
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Page 2 of 5Figure 3 Transverse view of upper lung field with tumor
located in the right upper lung apex. Chest computed
tomography (CT) done post intubation shows ground-glass
opacities, blebs confined to the right upper lung apex, and diffuse
ground-glass attenuation, blebs in the marginal areas, airspace
consolidation, and fibrosis in the bilateral upper and lower lung
fields.
Figure 4 Transverse view of the lower lung field.C h e s t
computed tomography (CT) done post intubation shows ground-
glass opacities, blebs confined to the right upper lung apex, and
diffuse ground-glass attenuation, blebs in the marginal areas,
airspace consolidation, and fibrosis in the bilateral upper and lower
lung fields.
Figure 5 Coronal view of the whole lung field. Chest computed
tomography (CT) done post intubation shows ground-glass
opacities, blebs confined to the right upper lung apex, and diffuse
ground-glass attenuation, blebs in the marginal areas, airspace
consolidation, and fibrosis in the bilateral upper and lower lung
fields.
Figure 6 Sagittal view of the whole lung field. Chest computed
tomography (CT) done post intubation shows ground-glass
opacities, blebs confined to the right upper lung apex, and diffuse
ground-glass attenuation, blebs in the marginal areas, airspace
consolidation, and fibrosis in the bilateral upper and lower lung
fields.
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Page 3 of 5(≥ 21 Gy), V20 (> 31%) [10], and ipsilateral V20 Gy [5]
correlates with radiation pneumonitis. Nonetheless, the
Radiation Therapy Oncology Group 0236 protocol using
SBRT via HT for NSCLC provided safe and effective
treatment when the V20 was restricted to less than 10%
to 15% [11]. The V15, V20, and mean lung dose for
each separate lung by divided course are shown in the
Table. Moreover, the whole-course V20 and mean total
lung dose were 10% and 10.24 Gy, respectively. Accord-
ing to previous reports [5,10,11], this plan was safe and
no symptomatic radiation pneumonitis occurred among
the NSCLC patients.
Erlotinib, an EGFR TKI, is an effective anti-tumor
agent for treatment of NSCLC among elderly patients
[1]. Erlotinib could be used as a single agent in select
subsets of patients with advanced NSCLC [12]. In a
comparative trial, only 0.8% of patients developed inter-
stitial lung disease in the erlotinib arm [13]. Moreover,
addition of standard-dose erlotinib to chemoradiother-
apy was feasible and without evidence of increased toxi-
cities [4]. However, prior tissue injury from radiation
therapy could lead to cells with altered responses when
the drug is subsequently applied [14]. Erlotinib
enhanced radiation responses including cell cycle arrest,
apoptosis induction, accelerated cellular repopulation,
and DNA damage repair [15]. Therefore, it is possible
for erlotinib to induce an altered response in cells when
erlotinib is applied after irradiation.
Though SBRT applied by HT allows for minimization
of normal tissue exposure to high radiation doses [16],
the large amount of low-dose irradiation to non-target
organs at risk (OAR), and thus, the incidence of lung
toxicity can become high [17]. Recently, non-target
OARs were impacted by arc therapy due to the low dose
bath phenomenon and these effects could be magnified
by agents known or unknown to be associated with recall
effects [18]. Irradiation modulates the anticancer drug’s
pharmacokinetics even under low doses and in off-target
areas [19]. Additionally, combined low-dose radiation
and erlotinib induced symptomatic pneumonitis in one
NSCLC patient [20]. Another NSCLC patient developed
radiation recall dermatitis induced by erlotinib [21].
According to these reports, we believe EGFR inhibitor
might not only enhance the effects of radiation, but also
might enhance the adverse effects of radiation, especially
when prescribed following previous concurrent treatment
with radition. Furthermore, radiation modulates the sys-
temic efficts of drugs regardless of the treatment effects
or side effects. Erlotinib appears to modulate the effects
of irradiation, both good and bad.
To our best knowledge, this is the first report of radia-
tion pneumonitis caused by erlotinib combined with
image-guided SBRT via HT with hypofractionation fol-
lowed by erlotinib presecribed for maintenance.
Oncologists should be alert to the potential risk of fatal
pulmonary toxicity caused by this multimodality treat-
ment. Radiotherapy plus targeting agents must be con-
ducted in well-designed clinical trials.
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